Epilepsy research in 2016: new treatment directions

The Lancet Neurology

Volumn 16, Issue 1, 2017, Pages 7-

  Berkovic, Samuel F ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GENERIC DRUG; HLA B ANTIGEN; LAMOTRIGINE; BUMETANIDE; LOOP DIURETIC AGENT;

ADVERSE OUTCOME; ANTICONVULSANT THERAPY; BIOEQUIVALENCE; CONSULTATION; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; ELECTROENCEPHALOGRAM; EPILEPSY; HUMAN; NOTE; PERSONALIZED MEDICINE; PHARMACOGENETICS; PREOPERATIVE EVALUATION; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEVENS JOHNSON SYNDROME; TEMPORAL LOBE EPILEPSY; TEMPORAL LOBECTOMY; TOXIC EPIDERMAL NECROLYSIS; TUBEROUS SCLEROSIS; DRUG RESISTANT EPILEPSY; MEDICAL RESEARCH; PROCEDURES; TREATMENT OUTCOME; TRENDS;

BIOMEDICAL RESEARCH; BUMETANIDE; DRUG RESISTANT EPILEPSY; EPILEPSY; EPILEPSY, TEMPORAL LOBE; HUMANS; PRECISION MEDICINE; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; TREATMENT OUTCOME;

EID: 85003875728     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(16)30334-9     Document Type: Note

References (8)

1. 1 Privitera, MD, Welty, TE, Gidal, BE, et al. Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial. Lancet Neurol 15 (2016), 365–372.
2. 2 Kesselheim, AS, Bykov, K, Gagne, JJ, Wang, SV, Choudhry, NK, Switching generic antiepileptic drug manufacturer not linked to seizures: a case-crossover study. Neurology 87 (2016), 1796–1801.
3. 3 Chen, P, Lin, JJ, Lu, CS, et al., Taiwan SJS Consortium. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 364 (2011), 1126–1133.
4. 4 Chen, Z, Liew, D, Kwan, P, Real-world cost-effectiveness of pharmacogenetic screening for epilepsy treatment. Neurology 86 (2016), 1086–1094.
5. 5 Barba, C, Rheims, S, Minotti, L, et al. Temporal plus epilepsy is a major determinant of temporal lobe surgery failures. Brain 139 (2016), 444–451.
6. 6 French, JA, Lawson, JA, Yapici, Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet 388 (2016), 2153–2163.
7. 7 Marguet, SL, Le-Schulte, VT, Merseburg, A, et al. Treatment during a vulnerable developmental period rescues a genetic epilepsy. Nat Med 21 (2015), 1436–1444.
8. 8 Pressler, RM, Boylan, GB, Marlow, N, et al., NEonatal seizure treatment with Medication Off-patent (NEMO) consortium. Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial. Lancet Neurol 14 (2015), 469–477.